The immunobiology and pathophysiology of primary biliary cirrhosis

Annual Review of Pathology: Mechanisms of Disease

Volumn 8, Issue , 2013, Pages 303-330

  Hirschfield, Gideon M ^a   Gershwin, M Eric ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Genomics; Mitochondria; Tolerance

Indexed keywords

AMINO ACID; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CARRIER PROTEIN; CELL ADHESION MOLECULE; CELL NUCLEUS ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEATH RECEPTOR 5; EPITOPE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; HLA DPB1 ANTIGEN; HLA DRB1 ANTIGEN; I KAPPA B KINASE BETA; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; MITOCHONDRION ANTIBODY; PYRUVATE DEHYDROGENASE COMPLEX; STAT4 PROTEIN; STRUCTURAL PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; XENOBIOTIC AGENT; AUTOANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; BACTERIURIA; CARDIOMYOPATHY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DESTRUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; EPITOPE MAPPING; FAMILY HISTORY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMICS; GEOGRAPHIC DISTRIBUTION; HLA SYSTEM; HORMONE SUBSTITUTION; HUMAN; IMMUNOBIOLOGY; IMMUNOPATHOLOGY; INNATE IMMUNITY; LIVER BIOPSY; MITOCHONDRION; MOLECULAR MIMICRY; MOUSE MAMMARY TUMOR ONCOVIRUS; NATURAL KILLER T CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEAR PORE COMPLEX; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRE T LYMPHOCYTE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN BINDING; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TH17 CELL; URINARY TRACT INFECTION; AMINO ACID SEQUENCE; ANIMAL; BILE DUCT; BILIARY CIRRHOSIS; BLOOD; IMMUNOLOGY; LIVER; MOLECULAR GENETICS; PATHOLOGY;

AMINO ACID SEQUENCE; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; BILE DUCTS; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; MOLECULAR SEQUENCE DATA;

MLCS; MLOWN;

EID: 84875890982     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-020712-164014     Document Type: Review

References (156)

1. Kaplan MM, Gershwin ME. 2005. Primary biliary cirrhosis. N. Engl. J. Med. 353:1261-733
2. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. 2011. Primary biliary cirrhosis. Lancet 377:1600-99
3. Gershwin ME, Mackay IR. 2008. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 47:737-455
4. Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, et al. 2006. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-βreceptor II dominant-negative mice. J. Immunol. 177:1655-600
5. Wakabayashi K, Lian ZX,Moritoki Y, Lan RY, Tsuneyama K, et al. 2006. IL-2 receptor α mice and the development of primary biliary cirrhosis. Hepatology 44:1240-499
6. Zhang W, Sharma R, Ju ST, He XS, Tao Y, et al. 2009. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatology 49:545-522
7. Yoshida K, Yang GX, Zhang W, Tsuda M, Tsuneyama K, et al. 2009. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor βreceptor type II mice. Hepatology 50:1494-5000
8. Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, et al. 2009. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N. Engl. J. Med. 360:2544-555
9. Liu X, Invernizzi P, Lu Y, Kosoy R, Bianchi I, et al. 2010. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat. Genet. 42:658-600
10. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. 2009. Primary biliary cirrhosis. Hepatology 50:291-3088
11. Mackay IR,Degail P. 1963. Thymic "germinal centres" and plasma cells in systemic lupus erythematosus. Lancet 2:6677
12. Walker JG, Doniach D, Roitt IM, Sherlock S. 1965. Serological tests in diagnosis of primary biliary cirrhosis. Lancet 1:827-311
13. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. 1987. Identification and specificity of a cDNA encoding the 70-kD mitochondrial antigen recognized in primary biliary cirrhosis. J. Immunol. 138:3525- 311
14. Kita H, Lian ZX, Van de Water J,He XS, Matsumura S, et al. 2002. Identification ofHLA-A2-restricted CD8+ cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J. Exp. Med. 195:113-233
15. Kita H, Matsumura S, He XS, Ansari AA, Lian ZX, et al. 2002. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J. Clin. Investig. 109:1231-400
16. Shimoda S, Harada K, Niiro H, Taketomi A, Maehara Y, et al. 2010. CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis. Hepatology 51:567-755
17. Shimoda S, Nakamura M, Ishibashi H, Kawano A, Kamihira T, et al. 2003. Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. Gastroenterology 124:1915-255
18. Shimoda S, Van de Water J, Ansari A,NakamuraM, Ishibashi H, et al. 1998. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J. Clin. Investig. 102:1831-400
19. Yeaman SJ, Fussey SP, Danner DJ, James OF, Mutimer DJ, Bassendine MF. 1988. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1:1067-700
20. Coppel RL, McNeilage LJ, Surh CD, Van de Water J, Spithill TW, et al. 1988. Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc. Natl. Acad. Sci. USA 85:7317-211
21. Fussey SP, Guest JR, James OF, Bassendine MF, Yeaman SJ. 1988. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc. Natl. Acad. Sci. USA 85:8654-588
22. Moteki S, Leung PS, Dickson ER, Van Thiel DH, Galperin C, et al. 1996. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology 23:436-444
23. Mackay IR, Whittingham S, Fida S, Myers M, Ikuno N, et al. 2000. The peculiar autoimmunity of primary biliary cirrhosis. Immunol. Rev. 174:226-377
24. Bruggraber SF, Leung PS, Amano K, Quan C, Kurth MJ, et al. 2003. Autoreactivity to lipoate and a conjugated form of lipoate in primary biliary cirrhosis. Gastroenterology 125:1705-133
25. Mao TK, Davis PA, Odin JA, Coppel RL, Gershwin ME. 2004. Sidechain biology and the immunogenicity of PDC-E2, the major autoantigen of primary biliary cirrhosis. Hepatology 40:1241-488
26. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. 1995. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J. Exp. Med. 181:1835-455
27. Shimoda S, Miyakawa H, Nakamura M, Ishibashi H, Kikuchi K, et al. 2008. CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. J. Autoimmun. 31:110-155
28. Lleo A, Shimoda S, Ishibashi H, GershwinME.2011. Primary biliary cirrhosis and autoimmune hepatitis: apotopes and epitopes. J. Gastroenterol. 46(Suppl. 1):29-388
29. Nakamura M, Takii Y, Ito M, Komori A, Yokoyama T, et al. 2006. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. J. Autoimmun. 26:138-455
30. Nakamura M, KondoH,MoriT,Komori A,Matsuyama M, et al. 2007. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45:118-277
31. BogdanosDP, Invernizzi P, Mackay IR,Vergani D. 2008. Autoimmune liver serology: current diagnostic and clinical challenges. World J. Gastroenterol. 14:3374-877
32. Janka C, Selmi C, Gershwin ME,Will H, Sternsdorf T. 2005. Small ubiquitin-related modifiers: a novel and independent class of autoantigens in primary biliary cirrhosis. Hepatology 41:609-166
33. Szostecki C,Will H, NetterHJ, Guldner HH. 1992. Autoantibodies to the nuclear Sp100 protein in primary biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin class distribution. Scand. J. Immunol. 36:555-644
34. Hirschfield GM, Liu X, Han Y, Gorlov IP, Lu Y, et al. 2010. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat. Genet. 42:655-577
35. Nakamura M, Yasunami M, Kondo H, Horie H, Aiba Y, et al. 2010. Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): The HLA-DRB1 polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC. Hepatol. Res. 40:494- 5044
36. Lleo A, Selmi C, Invernizzi P, Podda M, Coppel RL, et al. 2009. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology 49:871-799
37. Lleo A, Bowlus CL,YangGX, Invernizzi P, Podda M, et al. 2010. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology 52:987-988
38. Kahraman A, Gerken G, Canbay A. 2010. Apoptosis in immune-mediated liver diseases. Dig. Dis. 28:144- 499
39. Rong G, Zhong R, Lleo A, Leung PS, Bowlus CL, et al. 2011. Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology 54:196-2033
40. Lleo A, Invernizzi P, Selmi C, Coppel RL, Alpini G, et al. 2007. Autophagy: highlighting a novel player in the autoimmunity scenario. J. Autoimmun. 29:61-688
41. Lleo A, Selmi C, Invernizzi P, Podda M, Gershwin ME. 2008. The consequences of apoptosis in autoimmunity. J. Autoimmun. 31:257-622
42. Luedde T, Heinrichsdorff J, de Lorenzi R, de Vos R, Roskams T, Pasparakis M. 2008. IKK1 and IKK2 cooperate to maintain bile duct integrity in the liver. Proc. Natl. Acad. Sci. USA 105:9733-388
43. Takeda K, Kojima Y, Ikejima K, Harada K, Yamashina S, et al. 2008. Death receptor 5 mediated- apoptosis contributes to cholestatic liver disease. Proc. Natl. Acad. Sci. USA 105:10895-9000
44. Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, et al. 2011. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat. Genet. 43:329-322
45. Van de Water J, Turchany J, Leung PS, Lake J, Munoz S, et al. 1993. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex E2. J. Clin. Investig. 91:2653-644
46. Tsuneyama K, Van de Water J, Leung PS, Cha S, Nakanuma Y, et al. 1995. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression. Hepatology 21:1031-377
47. Tsuneyama K, Van de Water J, Van Thiel D, Coppel R, Ruebner B, et al. 1995. Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody- negative primary biliary cirrhosis. Hepatology 22:1440-466
48. Migliaccio C, Nishio A, Van de Water J, Ansari AA, Leung PS, et al. 1998. Monoclonal antibodies to mitochondrial E2 components define autoepitopes in primary biliary cirrhosis. J. Immunol. 161:5157-633
49. Migliaccio C, Van de Water J, Ansari AA, Kaplan MM, Coppel RL, et al. 2001. Heterogeneous response of antimitochondrial autoantibodies and bile duct apical staining monoclonal antibodies to pyruvate dehydrogenase complex E2: the molecule versus the mimic. Hepatology 33:792-8011
50. Matsumura S, Van de Water J, Leung P, Odin JA, Yamamoto K, et al. 2004. Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis. Hepatology 39:1415- 222
51. Kimura Y, Leung PS, Kenny TP, Van de Water J, Nishioka M, et al. 2002. Differential expression of intestinal trefoil factor in biliary epithelial cells of primary biliary cirrhosis. Hepatology 36:1227-355
52. Parikh-Patel A, Gold EB,Worman H, Krivy KE, Gershwin ME. 2001. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology 33:16-211
53. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, et al. 2005. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1,032 patients. Hepatology 42:1194-2022
54. CorpechotC,ChretienY,ChazouilleresO,Poupon R. 2010. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J. Hepatol. 53:162-699
55. Prince MI, Ducker SJ, James OF. 2010. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 59:508-122
56. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. 1996. Natural history of early primary biliary cirrhosis. Lancet 348:1399-4022
57. McNally RJ, James PW,Ducker S, James OF. 2011. Seasonal variation in the patient diagnosis of primary biliary cirrhosis: further evidence for an environmental component to etiology. Hepatology 54:2099-1033
58. Rieger R, Gershwin ME. 2007. The X and why of xenobiotics in primary biliary cirrhosis. J. Autoimmun. 28:76-844
59. Rieger R, Leung PS, JeddelohMR, KurthMJ, NantzMH, et al. 2006. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J. Autoimmun. 27:7-166
60. Rieger R, Oertelt S, Selmi C, Invernizzi P, Podda M, Gershwin ME. 2005. Decreased serum leptin levels in primary biliary cirrhosis: a link between metabolism and autoimmunity? Ann. N.Y. Acad. Sci. 1051:211-177
61. Long SA, Quan C, Van de Water J, Nantz MH, Kurth MJ, et al. 2001. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J. Immunol. 167:2956-633
62. Long SA, Van de Water J,GershwinME. 2002. Antimitochondrial antibodies in primary biliary cirrhosis: the role of xenobiotics. Autoimmun. Rev. 1:37-422
63. Naiyanetr P, Butler JD, Meng L, Pfeiff J, Kenny TP, et al. 2011. Electrophile-modified lipoic derivatives of PDC-E2 elicits anti-mitochondrial antibody reactivity. J. Autoimmun. 37:209-166
64. BurroughsAK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, BrumfittW, Sherlock S. 1984. Bacteriuria and primary biliary cirrhosis. Gut 25:133-377
65. Varyani FK, West J, Card TR. 2011. An increased risk of urinary tract infection precedes development of primary biliary cirrhosis. BMC Gastroenterol. 11:955
66. Smyk DS, Bogdanos DP, Kriese S, Billinis C, Burroughs AK, Rigopoulou EI. 2011. Urinary tract infection as a risk factor for autoimmune liver disease: from bench to bedside. Clin. Res. Hepatol. Gastroenterol. 36:110-211
67. Fussey SP, Ali ST, Guest JR, James OF, BassendineMF, Yeaman SJ. 1990. Reactivity of primary biliary cirrhosis sera with Escherichia coli dihydrolipoamide acetyltransferase (E2p): characterization of the main immunogenic region. Proc. Natl. Acad. Sci. USA 87:3987-911
68. BogdanosDP, Baum H, Grasso A, OkamotoM, Butler P, et al. 2004. Microbial mimics aremajor targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J. Hepatol. 40:31-399
69. BogdanosDP, Baum H, VerganiD, Burroughs AK. 2010. The role of E. coli infection in the pathogenesis of primary biliary cirrhosis. Dis. Markers 29:301-111
70. Bogdanos DP, Baum H, Okamoto M, Montalto P, Sharma UC, et al. 2005. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology 42:458-655
71. Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, et al. 2003. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 38:1250-577
72. Mattner J, Savage PB, Leung P, Oertelt SS, Wang V, et al. 2008. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 3:304-155
73. Amano K, Leung PS, Rieger R, Quan C, Wang X, et al. 2005. Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J. Immunol. 174:5874-833
74. Wakabayashi K, Lian ZX, Leung PS, Moritoki Y, Tsuneyama K, et al. 2008. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology 48:531-400
75. Wakabayashi K, Yoshida K, Leung PS, Moritoki Y, Yang GX, et al. 2009. Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. Clin. Exp. Immunol. 155:577-866
76. Ambrosini YM, Yang GX, ZhangW, Tsuda M, Shu S, et al. 2011. The multi-hit hypothesis of primary biliary cirrhosis: polyinosinic-polycytidylic acid (poly I:C) and murine autoimmune cholangitis. Clin. Exp. Immunol. 166:110-200
77. Leung PS, Park O, Tsuneyama K, Kurth MJ, Lam KS, et al. 2007. Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization. J. Immunol. 179:2651-577
78. MasonAL. 2011. The evidence supports a viral aetiology for primary biliary cirrhosis. J. Hepatol. 54:1312- 144
79. Selmi C. 2011. The evidence does not support a viral etiology for primary biliary cirrhosis. J. Hepatol. 54:1315-166
80. Xu L, Shen Z, Guo L, Fodera B, Keogh A, et al. 2003. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc. Natl. Acad. Sci. USA 100:8454-599
81. Selmi C, Ross SR, Ansari AA, Invernizzi P, Podda M, et al. 2004. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 127:493-5011
82. Johal H, Scott GM, Jones R, Camaris C, Riordan S, Rawlinson WD. 2009. Mouse mammary tumour virus-like virus (MMTV-LV) is present within the liver in a wide range of hepatic disorders and unrelated to nuclear p53 expression or hepatocarcinogenesis. J. Hepatol. 50:548-544
83. Simmons G, Glynn SA, Komaroff AL, Mikovits JA, Tobler LH, et al. 2011. Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science 334:814-177
84. SelmiC,Vergani D, Mieli-VerganiG. 2010. Viruses and autoantibodies in biliary atresia. Gastroenterology 139:1461-644
85. Selmi C, Zuin M, Meda F, Podda M, Biondi ML, Cecchini F. 2002. Common variants of the matrix metalloproteinase 3 (stromelysin) gene promoter in primary biliary cirrhosis. Gastroenterology 122:247-488
86. Aoki CA, Borchers AT, Li M, Flavell RA, Bowlus CL, et al. 2005. Transforming growth factor β (TGF-β) and autoimmunity. Autoimmun. Rev. 4:450-599
87. Aoki CA, Borchers AT, Ridgway WM, Keen CL, Ansari AA, Gershwin ME. 2005. NOD mice and autoimmunity. Autoimmun. Rev. 4:373-799
88. Aoki CA, Bowlus CL, Gershwin ME. 2005. The immunobiology of primary sclerosing cholangitis. Autoimmun. Rev. 4:137-433
89. Aoki CA,DawsonK,Kenny TP, Gershwin ME, BowlusCL. 2006. Gene expression byPBMCin primary sclerosing cholangitis: evidence for dysregulation of immunemediated genes. Clin. Dev. Immunol. 13:265- 711
90. Aoki CA, Roifman CM, Lian ZX, Bowlus CL, Norman GL, et al. 2006. IL-2 receptor αdeficiency and features of primary biliary cirrhosis. J. Autoimmun. 27:50-533
91. Selmi C. 2010. The worldwide gradient of autoimmune conditions. Autoimmun. Rev. 9:247-50AA
92. Arnson Y, Shoenfeld Y, Amital H. 2010. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J. Autoimmun. 34:258-65JJ
93. BrooksWH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y. 2010. Epigenetics and autoimmunity. J. Autoimmun. 34:207-19JJ
94. Chang C. 2010. The immune effects of naturally occurring and synthetic nanoparticles. J. Autoimmun. 34:234-46JJ
95. Chang C, Gershwin ME. 2010. Drugs and autoimmunity - a contemporary review and mechanistic approach. J. Autoimmun. 34:266-75JJ
96. Maverakis E, Miyamura Y, BowenMP, CorreaG,Ono Y, GoodarziH. 2010. Light, including ultraviolet. J. Autoimmun. 34:247-57JJ
97. Round JL, O'Connell RM, Mazmanian SK. 2010. Coordination of tolerogenic immune responses by the commensal microbiota. J. Autoimmun. 34:220-25JJ
98. Tanaka A, Lindor K, Gish R, Batts K, Shiratori Y, et al. 1999. Fetal microchimerism alone does not contribute to the induction of primary biliary cirrhosis. Hepatology 30:833-388
99. Fanning PA, Jonsson JR, Clouston AD, Edwards-Smith C, Balderson GA, et al. 2000. Detection of male DNA in the liver of female patients with primary biliary cirrhosis. J. Hepatol. 33:690-955
100. Corpechot C, Barbu V, Chazouilleres O, Poupon R. 2000. Fetal microchimerism in primary biliary cirrhosis. J. Hepatol. 33:696-7000
101. Alvaro D, MancinoMG, Onori P, Franchitto A, Alpini G, et al. 2006. Estrogens and the pathophysiology of the biliary tree. World J. Gastroenterol. 12:3537-455
102. Bianchi I, Lleo A, GershwinME, Invernizzi P. 2011. The X chromosome and immune associated genes. J. Autoimmun. 38:187-92JJ
103. Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Grati FR, et al. 2004. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 363:533-355
104. Miozzo M, Selmi C, Gentilin B, Grati FR, Sirchia S, et al. 2007. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology 46:456-622
105. Mitchell MM, Lleo A, Zammataro L, Mayo MJ, Invernizzi P, et al. 2011. Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. Epigenetics 6:95-1022
106. Krams SM, Surh CD, Coppel RL, Ansari A, Ruebner B, Gershwin ME. 1989. Immunization of experimental animals with dihydrolipoamide acetyltransferase, as a purified recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis. Hepatology 9:411-166
107. Krams SM, Dorshkind K, Gershwin ME. 1989. Generation of biliary lesions after transfer of human lymphocytes into severe combined immunodeficient (SCID) mice. J. Exp. Med. 170:1919-300
108. Masanaga T, Watanabe Y, Van de Water J, Leung PS, Nakanishi T, et al. 1998. Induction and persistence of immune-mediated cholangiohepatitis in neonatally thymectomized mice. Clin. Immunol. Immunopathol. 89:141-499
109. Tsuneyama K, Nose M, Nisihara M, Katayanagi K, Harada K, Nakanuma Y. 2001. Spontaneous occurrence of chronic non-suppurative destructive cholangitis and antimitochondrial autoantibodies in MRL/lpr mice: possible animal model for primary biliary cirrhosis. Pathol. Int. 51:418-244
110. Ohba K, Omagari K, Murase K, Hazama H, Masuda J, et al. 2002. A possible mouse model for spontaneous cholangitis: serological and histological characteristics of MRL/lpr mice. Pathology 34:250-566
111. Saitoh T, Fujiwara M, Nomoto M, Makino M, Watanabe H, et al. 1988. Hepatic lesions induced by graft-versus-host reaction across MHC class II antigens: an implication for animal model of primary biliary cirrhosis. Clin. Immunol. Immunopathol. 49:166-722
112. Kimura T, Suzuki K, Inada S, Hayashi A, Saito H, et al. 1994. Induction of autoimmune disease by graft-versus-host reaction acrossMHC class II difference: modification of the lesions in IL-6 transgenic mice. Clin. Exp. Immunol. 95:525-299
113. Irie J, Wu Y, Wicker LS, Rainbow D, Nalesnik MA, et al. 2006. NOD. c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J. Exp. Med. 203:1209-199
114. Yang GX, Lian ZX, Chuang YH, Moritoki Y, Lan RY, et al. 2008. Adoptive transfer of CD8+ T cells from transforming growth factor β receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology 47:1974-822
115. Moritoki Y, Lian ZX, Lindor K, Tuscano J, Tsuneyama K, et al. 2009. B cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor βreceptor II dominant negative mice. Hepatology 50:1893-9033
116. Chuang YH, Lian ZX, Yang GX, Shu SA,Moritoki Y, et al. 2008. Natural killer T cells exacerbate liver injury in a transforming growth factor βreceptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology 47:571-800
117. Hsu W, Zhang W, Tsuneyama K, Moritoki Y, Ridgway WM, et al. 2009. Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Rα mice. Hepatology 49:133-400
118. Janse M, Lamberts LE, Franke L, Raychaudhuri S, Ellinghaus E, et al. 2011. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology 53:1977-855
119. Salas JT, Banales JM, Sarvide S, Recalde S, Ferrer A, et al. 2008. Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 134:1482- 933
120. Hirschfield GM, Invernizzi P. 2011. Progress in the genetics of primary biliary cirrhosis. Semin. Liver Dis. 31:147-566
121. Lazaridis KN, Juran BD, Boe GM, Slusser JP, de Andrade M, et al. 2007. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 46:785-922
122. SelmiC,MayoMJ, Bach N, Ishibashi H, Invernizzi P, et al. 2004. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 127:485-922
123. Arbour L, Rupps R, Field L, Ross P, Erikson A, et al. 2005. Characteristics of primary biliary cirrhosis in British Columbia's First Nations population. Can. J. Gastroenterol. 19:305-100
124. Donaldson PT, Baragiotta A, Heneghan MA, Floreani A, Venturi C, et al. 2006. HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Hepatology 44:667- 744
125. Invernizzi P, Selmi C, Poli F, Frison S, Floreani A, et al. 2008. Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1,992 healthy controls. Hepatology 48:1906-122
126. Umemura T, Joshita S, Ichijo T, Yoshizawa K, Katsuyama Y, et al. 2011. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. Hepatology 55:506-111
127. Walker EJ, Hirschfield GM, Xu C, Lu Y, Liu X, et al. 2009. CTLA4/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in theCanadian population. Arthritis Rheum. 60:931-377
128. Hirschfield GM, Xie G, Lu E, Sun Y, Juran BD, et al. 2012. Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes Immun. 13:328-355
129. Hirschfield GM, Siminovitch KA. 2009. Toward the molecular dissection of primary biliary cirrhosis. Hepatology 50:1347-500
130. Padgett KA, Lan RY, Leung PC, Lleo A, Dawson K, et al. 2009. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J. Autoimmun. 32:246-533
131. Selmi C, Podda M, Gershwin ME. 2009. Old and rising stars in the lymphoid liver. Semin. Immunopathol. 31:279-822
132. Alabraba EB, Lai V, Boon L, Wigmore SJ, Adams DH, Afford SC. 2008. Coculture of human liver macrophages and cholangiocytes leads to CD40-dependent apoptosis and cytokine secretion. Hepatology 47:552-622
133. Lleo A, Liao J, Invernizzi P, Zhao M, Bernuzzi F, et al. 2012. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology 55:153-600
134. Van de Water J,AnsariA,Prindiville T, CoppelRL, Ricalton N, et al. 1995. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J. Exp. Med. 181:723-333
135. Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, et al. 2010. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatoryTcells in the inflamed human liver. J. Immunol. 184:2886-988
136. Lan RY, Cheng C, Lian ZX, Tsuneyama K, Yang GX, et al. 2006. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 43:729-377
137. Lan RY, Salunga TL, Tsuneyama K, Lian ZX, Yang GX, et al. 2009. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J. Autoimmun. 32:43-511
138. Kikuchi K, Lian ZX, Yang GX, Ansari AA, Ikehara S, et al. 2005. Bacterial CpG induces hyper-IgM production in CD27+ memory B cells in primary biliary cirrhosis. Gastroenterology 128:304-122
139. Selmi C, Lleo A, Pasini S, ZuinM, GershwinME. 2009. Innate immunity and primary biliary cirrhosis. Curr. Mol. Med. 9:45-511
140. Mao TK, Lian ZX, Selmi C, Ichiki Y, Ashwood P, et al. 2005. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology 42:802-88
141. Trauner M, Halilbasic E. 2011. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 140:1120-255
142. Wang YD, Chen WD,WangM, YuD, Forman BM, HuangW. 2008. Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response. Hepatology 48:1632-433
143. Mencarelli A, Renga B,Migliorati M, Cipriani S,Distrutti E, et al. 2009. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J. Immunol. 183:6657-666
144. Trauner M, Halilbasic E. 2011. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 140:1120-255
145. Fickert P, Fuchsbichler A,Moustafa T, Wagner M, Zollner G, et al. 2009. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am. J. Pathol. 175:2392-4055
146. Prieto J, Garcia N, Marti-Climent JM, Penuelas I, Richter JA, Medina JF. 1999. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 117:167-722
147. Arenas F, Hervias I, Uriz M, Joplin R, Prieto J, Medina JF. 2008. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J. Clin. Investig. 118:695-7099
148. Chuang YH, Lan RY, Gershwin ME. 2009. The immunopathology of human biliary cell epithelium. Semin. Immunopathol. 31:323-311
149. Van de Water J,GersonLB, Ferrell LD,Lake JR, CoppelRL, et al. 1996. Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology 24:1079-844
150. Lindor K. 2007. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N. Engl. J. Med. 357:1524-299
151. Beuers U. 2006. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3:318-288
152. Beuers U, Hohenester S, de BuyWenniger LJ, Kremer AE, Jansen PL, Elferink RP. 2010. The biliary HCO3 umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 52:1489-966
153. Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, et al. 2009. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2mice. Hepatology 49:1972-811
154. Tsuda M, Moritoki Y, Lian ZX, Zhang W, Yoshida K, et al. 2012. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 55:512-211
155. Lleo A, Invernizzi P, Mackay IR, PrinceH,Zhong RQ,GershwinME. 2008. Etiopathogenesis of primary biliary cirrhosis. World J. Gastroenterol. 14:3328-377
156. Zeman MV, Hirschfield GM. 2010. Autoantibodies and liver disease: uses and abuses. Can. J. Gastroenterol. 24:225-311